These findings demonstrate meaningful and durable responses, particularly in strongly HER2-positive tumors, supporting the tumor-agnostic therapeutic potential of T-DXd across HER2-expressing solid malignancies, including cervical carcinoma. This evidence concerns the gene ERBB2 and neoplasm.